The management of testicular cancer in Victoria, 1988-1993

---

• 1.
• McKiernan JM, Goluboff ET, Liberson GL, et al. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 1999; 162: 361-363.
• 2.
• Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
• 3.
• Bosl GJ, Geller NL, Cirrincione C, et al. Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience. Am J Med 1983; 75: 29-35.
• 4.
• International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
• 5.
• Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10: 1762-1768.
• 6.
• Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981; 41: 3275-3280.
• 7.
• Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990; 8: 1683-1694.
• 8.
• SPSS Inc. SPSS-X user's guide. 3rd ed. New York: McGraw-Hill; 1988.
• 9.
• Hedelin G. RELSURV: a program for relative survival. Technical report of the Department of Epidemiology and Public Health, Faculty of Medicine. Strasbourg, France: Louis Pasteur University, 1995.
• 10.
• Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter. Lancet 1993; 341: 999-1002.
• 11.
• Hernes EH, Harstad K, Fossa SD. Changing incidence and delay of testicular cancer in southern Norway (1981-1992). Eur Urol 1996; 30: 349-357.
• 12.
• Feuer EJ, Frey CM, Brawley OW, et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 1994; 12: 368-377.
• 13.
• Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999; 91: 839-846.
• 14.
• Ries LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.
• 15.
• Stone JM, Cruickshank DG, Sandeman TF, Matthews JP. Trebling of the incidence of testicular cancer in Victoria, Australia (1950-1985). Cancer 1991; 68: 211-219.
• 16.
• Bergstrom R, Adami HO, Mohner M, et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst 1996; 88: 727-733.
• 17.
• Horwich A, Peckham MJ. Surveillance after orchidectomy for clinical stage I germ-cell tumours of the testis. Prog Clin Biol Res 1988; 269: 471-479.
• 18.
• Boyer MJ, Cox K, Tattersall MH, et al. Active surveillance after orchidectomy for nonseminomatous testicular germ cell tumors: late relapse may occur.Urology 1997; 50: 588-592.